+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating autologous cell therapy to study its safety and potential to treat pain and inflammation associated with Osteoarthritis of the hip. This prospective open-label study initially includes 50 patients, with a larger follow-up group planned involving 4,000 patients. The condition involves degeneration or chronic injury affecting the hip joint. Patients will receive autologous StroMed cells obtained using the Adipose Ultrasonic Cell Recovery Unit and Platelet Rich Plasma PRP processed by the RegenLab RegenKit BCT-3. These will be injected directly into the affected hip joints. The treatment schedule includes an initial combined injection of StroMed and PRP on day 0, followed by PRP injections alone on days 7, 14, and 30. This approach uses a mechanical process without enzymes or drugs, aiming to minimize risks. Participants will be monitored through laboratory tests for inflammation markers, hip disability and osteoarthritis outcome score HOOS questionnaires, and follow-up MRIs up to 6 months. Additional assessments include SF-36 quality of life surveys and numerical rating scales for pain. Researchers will also observe any changes in medication use or delays in hip replacement surgery. The study measures changes in HOOS scores primarily at 0, 2, and 6 months.

Age: 18Years - 90YearsAll GendersPhase 2
1 location
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and potential treatment effects of autologous cell therapy for pain and inflammation caused by osteoarthritis of the knee. This prospective open-label clinical trial initially includes 50 patients, with plans for a larger follow-up study involving 4,000 participants. The trial focuses on patients suffering from knee osteoarthritis due to degeneration or chronic injury. Participants will receive autologous Stromed cells obtained through a mechanical process without enzymes or drugs, combined with Platelet Rich Plasma PRP processed by RegenLab. The treatment involves direct injections into the affected knee joints. Patients are divided into two groups Cohort 1 receives PRP injections at the time of initial StroMed treatment and then at 1 week, 2 weeks, and 1 month Cohort 2 receives PRP at the initial treatment and then at 1 month and 2 months. During the study, patient outcomes will be monitored through MRI scans at various points up to 6 months, blood tests for inflammation markers, and questionnaires including the Knee Osteoarthritis Outcome Score KOOS, the SF-36 quality of life survey, and numerical rating scales for pain. Researchers will also observe any reduction in medication use or delay in knee replacement surgery. The trial runs from July 2015 to August 2026 and includes regular follow-ups to assess safety and effectiveness.

Age: 18Years - 90YearsAll GendersPhase 2
1 location
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating autologous cell therapy as a potential treatment for pain and inflammation caused by Osteoarthritis of the shoulder. This open-label study aims to assess the safety and treatment potential of this approach in 50 patients, with plans for a larger follow-up study involving 4,000 patients. The study is sponsored by VivaTech International, Inc. and focuses on patients with shoulder osteoarthritis due to degeneration or chronic injury. Participants will receive autologous StroMed cells obtained using the Adipose Ultrasonic Cell Recovery Unit and Platelet Rich Plasma PRP processed by the RegenLab RegenKit BCT-3. These treatments are given as direct injections into the affected shoulder joints, with an initial combined injection of StroMed and PRP on day 0, followed by PRP injections on days 7 and 14. The StroMed cells are mechanically processed without enzymes or drugs, maintaining the extracellular matrix and minimizing risk to patients. Throughout the study, participants will undergo laboratory tests to track inflammation markers and complete several questionnaires including the DASH, SPADI, SF-36 quality of life, and Numerical Rating Scale for pain at 0, 2, and 6 months. MRI scans of the affected joint will be performed at baseline and optionally at 6 months to assess changes. Researchers will monitor safety, treatment effects, medication use, and any delay in shoulder replacement plans over a six-month period.

Age: 18Years - 90YearsAll GendersPhase 2
1 location